|
Market Closed -
Other stock markets
|
After hours 05:30:00 am | |||
| 314.05 USD | -0.04% |
|
315.25 | +0.38% |
| 15/04 | Baird Adjusts Price Target on UnitedHealth to $278 From $291, Maintains Underperform Rating | MT |
| 13/04 | States, insurers await needed details to implement new US Medicaid work rules | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 7.32 | 7.76 | 7.79 | 7.06 | 3.9 | |||||
Return on Total Capital | 12.44 | 13.1 | 13.03 | 11.67 | 6.51 | |||||
Return On Equity % | 24.12 | 25.35 | 24.98 | 15.13 | 12.54 | |||||
Return on Common Equity | 25.19 | 26.91 | 26.88 | 15.88 | 12.91 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 24.22 | 24.56 | 24.48 | 22.33 | 18.53 | |||||
SG&A Margin | 14.8 | 14.74 | 14.7 | 13.24 | 13.31 | |||||
EBITDA Margin % | 9.09 | 9.51 | 9.45 | 8.74 | 4.83 | |||||
EBITA Margin % | 8.75 | 9.17 | 9.14 | 8.49 | 4.62 | |||||
EBIT Margin % | 8.33 | 8.77 | 8.71 | 8.07 | 4.24 | |||||
Income From Continuing Operations Margin % | 6.17 | 6.37 | 6.23 | 3.81 | 2.86 | |||||
Net Income Margin % | 6.01 | 6.21 | 6.02 | 3.6 | 2.69 | |||||
Net Avail. For Common Margin % | 6.01 | 6.21 | 6.02 | 3.6 | 2.69 | |||||
Normalized Net Income Margin | 4.69 | 4.92 | 4.69 | 4.22 | 1.92 | |||||
Levered Free Cash Flow Margin | 6.39 | 7.02 | 5.33 | 2.89 | 3.1 | |||||
Unlevered Free Cash Flow Margin | 6.75 | 7.43 | 5.88 | 3.5 | 3.66 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.4 | 1.42 | 1.43 | 1.4 | 1.47 | |||||
Fixed Assets Turnover | 52.9 | 57.3 | 60.04 | 70.52 | 92.89 | |||||
Receivables Turnover (Average Receivables) | 19.42 | 18.6 | 17.31 | 16.66 | 18.06 | |||||
Inventory Turnover (Average Inventory) | - | - | 89.1 | 94.21 | 102.72 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.73 | 0.73 | 0.75 | 0.83 | 0.79 | |||||
Quick Ratio | 0.66 | 0.65 | 0.69 | 0.75 | 0.7 | |||||
Operating Cash Flow to Current Liabilities | 0.29 | 0.29 | 0.29 | 0.23 | 0.17 | |||||
Days Sales Outstanding (Average Receivables) | 18.8 | 19.63 | 21.08 | 21.97 | 20.21 | |||||
Days Outstanding Inventory (Average Inventory) | - | - | 4.1 | 3.89 | 3.55 | |||||
Average Days Payable Outstanding | 78.29 | 79.03 | 78.96 | 77.99 | 73.14 | |||||
Cash Conversion Cycle (Average Days) | - | - | -53.78 | -52.14 | -49.38 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 65.74 | 72.33 | 68.17 | 79.73 | 81.62 | |||||
Total Debt / Total Capital | 39.66 | 41.97 | 40.54 | 44.36 | 44.94 | |||||
LT Debt/Equity | 59.87 | 67.57 | 62.8 | 74.31 | 74.62 | |||||
Long-Term Debt / Total Capital | 36.12 | 39.21 | 37.34 | 41.35 | 41.08 | |||||
Total Liabilities / Total Assets | 63.96 | 64.86 | 63.86 | 65.61 | 67.15 | |||||
EBIT / Interest Expense | 14.44 | 13.59 | 9.97 | 8.27 | 4.74 | |||||
EBITDA / Interest Expense | 16.48 | 15.36 | 11.25 | 9.32 | 5.8 | |||||
(EBITDA - Capex) / Interest Expense | 15 | 14.02 | 10.21 | 8.42 | 4.9 | |||||
Total Debt / EBITDA | 1.84 | 1.94 | 1.85 | 2.25 | 3.57 | |||||
Net Debt / EBITDA | 1.06 | 1.22 | 1.15 | 1.55 | 2.52 | |||||
Total Debt / (EBITDA - Capex) | 2.02 | 2.13 | 2.03 | 2.49 | 4.23 | |||||
Net Debt / (EBITDA - Capex) | 1.16 | 1.33 | 1.27 | 1.72 | 2.99 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 11.84 | 12.71 | 14.64 | 7.71 | 11.81 | |||||
Gross Profit, 1 Yr. Growth % | 3.96 | 14.31 | 14.24 | -1.71 | -7.25 | |||||
EBITDA, 1 Yr. Growth % | 6.81 | 17.81 | 13.93 | -0.41 | -38.19 | |||||
EBITA, 1 Yr. Growth % | 7.08 | 18.14 | 14.2 | 0.09 | -39.2 | |||||
EBIT, 1 Yr. Growth % | 6.98 | 18.63 | 13.8 | -0.22 | -41.26 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 12.45 | 16.39 | 12.14 | -34.14 | -15.98 | |||||
Net Income, 1 Yr. Growth % | 12.22 | 16.4 | 11.24 | -35.64 | -16.31 | |||||
Normalized Net Income, 1 Yr. Growth % | 7.14 | 18.14 | 9.32 | -3.05 | -49.11 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 12.79 | 17.15 | 12.65 | -35 | -14.7 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -1.64 | 9.85 | 9.02 | -24.19 | -3.13 | |||||
Inventory, 1 Yr. Growth % | - | - | -20 | 35.71 | -13.16 | |||||
Accounts Receivable, 1 Yr. Growth % | 10.46 | 24.37 | 20.33 | 5.12 | 2.92 | |||||
Total Assets, 1 Yr. Growth % | 7.56 | 15.79 | 11.4 | 8.97 | 3.79 | |||||
Common Equity, 1 Yr. Growth % | 9.57 | 8.38 | 14.12 | 4.4 | 1.57 | |||||
Tangible Book Value, 1 Yr. Growth % | -11.04 | 93.62 | 2.86 | 22.29 | -0.28 | |||||
Cash From Operations, 1 Yr. Growth % | 0.76 | 17.29 | 10.92 | -16.73 | -18.62 | |||||
Capital Expenditures, 1 Yr. Growth % | 19.65 | 14.18 | 20.84 | 3.34 | 3.52 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -8.21 | 18.24 | -16.59 | -44.5 | 10.13 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -7.81 | 18.64 | -12.85 | -38.75 | 8.88 | |||||
Dividend Per Share, 1 Yr. Growth % | 15.94 | 14.29 | 13.91 | 12.21 | 6.72 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 8.98 | 12.28 | 13.67 | 11.12 | 9.74 | |||||
Gross Profit, 2 Yr. CAGR % | 9.97 | 9.01 | 14.28 | 5.97 | -4.52 | |||||
EBITDA, 2 Yr. CAGR % | 9.82 | 12.2 | 15.85 | 6.52 | -21.54 | |||||
EBITA, 2 Yr. CAGR % | 10.31 | 12.47 | 16.15 | 6.91 | -21.99 | |||||
EBIT, 2 Yr. CAGR % | 10.35 | 12.66 | 16.19 | 6.56 | -23.44 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 11.59 | 14.4 | 14.25 | -14.06 | -25.61 | |||||
Net Income, 2 Yr. CAGR % | 11.76 | 14.29 | 13.79 | -15.39 | -26.61 | |||||
Normalized Net Income, 2 Yr. CAGR % | 11.59 | 12.5 | 13.65 | 2.95 | -29.76 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 12.32 | 14.95 | 14.88 | -14.43 | -25.54 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -3.02 | 3.94 | 9.43 | -9.09 | -14.3 | |||||
Inventory, 2 Yr. CAGR % | - | - | - | 4.2 | 8.56 | |||||
Accounts Receivable, 2 Yr. CAGR % | 9.66 | 17.21 | 22.34 | 12.47 | 4.01 | |||||
Total Assets, 2 Yr. CAGR % | 10.47 | 11.6 | 13.57 | 10.18 | 6.35 | |||||
Common Equity, 2 Yr. CAGR % | 11.6 | 8.97 | 11.21 | 9.15 | 2.97 | |||||
Tangible Book Value, 2 Yr. CAGR % | -9.09 | 31.25 | 41.12 | 12.16 | 10.43 | |||||
Cash From Operations, 2 Yr. CAGR % | 10.01 | 8.71 | 14.06 | -3.9 | -17.68 | |||||
Capital Expenditures, 2 Yr. CAGR % | 8.85 | 16.88 | 17.46 | 11.75 | 3.43 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 8.96 | 6.62 | 1.46 | -30.2 | -18.47 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 8.33 | 6.9 | 3.77 | -25.23 | -15.44 | |||||
Dividend Per Share, 2 Yr. CAGR % | 16.3 | 15.11 | 14.1 | 13.05 | 9.43 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 8.33 | 10.21 | 13.06 | 11.65 | 11.35 | |||||
Gross Profit, 3 Yr. CAGR % | 8.96 | 11.4 | 10.73 | 8.68 | 1.36 | |||||
EBITDA, 3 Yr. CAGR % | 10.91 | 12.45 | 12.77 | 10.16 | -11.15 | |||||
EBITA, 3 Yr. CAGR % | 11.33 | 12.86 | 13.05 | 10.53 | -11.42 | |||||
EBIT, 3 Yr. CAGR % | 11.39 | 13.04 | 13.03 | 10.44 | -12.63 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 12.72 | 13.17 | 13.64 | -4.92 | -14.71 | |||||
Net Income, 3 Yr. CAGR % | 12.98 | 13.29 | 13.26 | -5.89 | -15.69 | |||||
Normalized Net Income, 3 Yr. CAGR % | 12.15 | 13.73 | 11.43 | 7.79 | -18.6 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 14.04 | 13.91 | 14.18 | -4.98 | -14.52 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | -2.17 | 1.09 | 5.61 | -3.17 | -7.14 | |||||
Inventory, 3 Yr. CAGR % | - | - | - | - | -1.94 | |||||
Accounts Receivable, 3 Yr. CAGR % | 7.67 | 14.36 | 18.24 | 16.3 | 9.19 | |||||
Total Assets, 3 Yr. CAGR % | 11.71 | 12.21 | 11.53 | 12.02 | 8.01 | |||||
Common Equity, 3 Yr. CAGR % | 11.55 | 10.52 | 10.66 | 8.89 | 6.56 | |||||
Tangible Book Value, 3 Yr. CAGR % | -2.82 | 16.97 | 21.01 | 34.54 | 7.85 | |||||
Cash From Operations, 3 Yr. CAGR % | 12.45 | 12.38 | 9.44 | 2.7 | -9.08 | |||||
Capital Expenditures, 3 Yr. CAGR % | 5.96 | 10.6 | 18.19 | 12.55 | 8.93 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 15.9 | 13.71 | -0.35 | -15.6 | -16.44 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 15.26 | 13.31 | 1.22 | -11.6 | -13.25 | |||||
Dividend Per Share, 3 Yr. CAGR % | 17.52 | 15.63 | 14.71 | 13.46 | 10.9 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 9.24 | 10.01 | 10.43 | 10.57 | 11.72 | |||||
Gross Profit, 5 Yr. CAGR % | 9.93 | 11.11 | 11.05 | 9.19 | 4.36 | |||||
EBITDA, 5 Yr. CAGR % | 12.5 | 12.77 | 12.88 | 10.04 | -2.46 | |||||
EBITA, 5 Yr. CAGR % | 12.75 | 13.05 | 13.23 | 10.44 | -2.54 | |||||
EBIT, 5 Yr. CAGR % | 13.14 | 13.33 | 13.28 | 10.4 | -3.28 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 20.18 | 13.78 | 13.33 | 1.37 | -4.08 | |||||
Net Income, 5 Yr. CAGR % | 19.76 | 13.77 | 13.3 | 0.8 | -4.78 | |||||
Normalized Net Income, 5 Yr. CAGR % | 12.9 | 13.41 | 12.74 | 9.29 | -7.35 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 20.05 | 14.59 | 14.38 | 1.6 | -3.77 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 6.85 | 5.1 | 2.32 | -3.11 | -2.86 | |||||
Accounts Receivable, 5 Yr. CAGR % | 11.76 | 13.07 | 13.32 | 13.6 | 12.33 | |||||
Total Assets, 5 Yr. CAGR % | 11.56 | 12.06 | 12.45 | 11.4 | 9.43 | |||||
Common Equity, 5 Yr. CAGR % | 13.4 | 10.24 | 11.42 | 9.97 | 7.52 | |||||
Tangible Book Value, 5 Yr. CAGR % | -2.35 | 14.12 | 12.82 | 15.02 | 16.66 | |||||
Cash From Operations, 5 Yr. CAGR % | 17.93 | 14.02 | 13.09 | 5.56 | -2.34 | |||||
Capital Expenditures, 5 Yr. CAGR % | 7.55 | 6.73 | 10.42 | 11.06 | 12.05 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 9.99 | 11.06 | 10.91 | -5.65 | -7.09 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 9.95 | 11.11 | 11.49 | -3.27 | -4.92 | |||||
Dividend Per Share, 5 Yr. CAGR % | 18.71 | 17.36 | 16.14 | 14.59 | 12.57 |
- Stock Market
- Equities
- UNH Stock
- Financials UnitedHealth Group Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















